Conference Coverage

Cannabis for pain linked to slight risk for arrhythmia


 

FROM ESC CONGRESS 2022

Cancer, musculoskeletal, and neurologic pain

For this analysis, the researchers identified 1.8 million patients in Denmark who were diagnosed with chronic pain between 2018 and 2021.

Of those, around 5,000 patients had claimed at least one prescription of medicinal cannabis (dronabinol 29%, cannabinoids 46%, or cannabidiol 25%).

The patients had a median age of 60 years, and 63% were women.

The cannabis users had been prescribed this therapy for musculoskeletal (35%), cancer (18%), neurological (14%), or other (33%) pain, Dr. Nouhravesh said.

The researchers and Dr. Olshansky have no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

COVID-19 and risk of clotting: ‘Be proactive about prevention’
MDedge Rheumatology
CVD deaths rose, imaging declined during pandemic
MDedge Rheumatology
New-onset arrhythmias low in COVID-19 and flu
MDedge Rheumatology
New-AFib risk may not rise with light drinking, may fall with wine
MDedge Rheumatology
Tachycardia syndrome may be distinct marker for long COVID
MDedge Rheumatology
Coffee drinking in midlife tied to heart benefits
MDedge Rheumatology
Growing proportion of cardiac arrests in U.S. considered opioid related
MDedge Rheumatology
Alcoholic drinks stand out in novel trial exploring AFib triggers
MDedge Rheumatology
‘Substantial’ CVD risks, burden up to a year after COVID-19
MDedge Rheumatology
Cardiac arrest survival lower in COVID-19 inpatients
MDedge Rheumatology